bioAffinity Technologies, Inc. (BIAF) ownership: insiders 19% · institutions 3% · index and ETF funds 0% (13F 2026-03-31). Insider activity, 90 days: 0 sales, 0 open-market buys. SEC EDGAR first-party data.
| Holder | Shares | Market Value | % Outstanding | Reported |
|---|---|---|---|---|
| Vanguard | 86614.00 | $331732.00 | 1.1% | 2026-03-31 |
| Geode Capital Management | 48293.00 | $184961.00 | 0.6% | 2026-03-31 |
| J. Safra Sarasin Holding AG | 42600.00 | $164010.00 | 0.5% | 2026-03-31 |
| Schonfeld Strategic Advisors LLC | 24413.00 | $93500.00 | 0.3% | 2026-03-31 |
| State Street | 14386.00 | $55098.00 | 0.2% | 2026-03-31 |
| Renaissance Technologies | 22967.00 | $49609.00 | 0.3% | 2026-03-31 |
| Northern Trust | 12725.00 | $48737.00 | 0.2% | 2026-03-31 |
| UBS | 9214.00 | $35290.00 | 0.1% | 2026-03-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2025-01-10 | |
| Sell | null | 2025-01-10 | |
| Sell | null | 2025-01-10 | |
| Sell | null | 2025-01-10 | |
| Sell | null | 2025-01-10 | |
| Sell | null | 2024-11-05 | |
| Sell | null | 2024-07-01 | |
| Sell | null | 2024-07-01 |
Back to BIAF overview · BIAF earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.